

ASX Announcement

Medibio Limited – 23 February 2023



Section 708A Cleansing Notice

The Directors of Medibio Limited (ASX: **MEB**, “**Medibio**” or the “**Company**”) advise that the Company has issued 830,000,000 fully paid ordinary shares (**Shares**) at an issue price of \$0.0015 per share.

The Company confirms that:

- (a) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) the Company is providing this notice under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has compiled with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company;
and
 - (ii) section 674 of the Corporations Act as it applies to the Company; and
- (d) as at the date of this announcement, there is no excluded information of the type referred to in Section 708A(7) and 708A(8) of the Corporations Act.

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

For Further information:

Mathew Watkins
Company Secretary
T: +61 3 9692 7222

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.